Trevi Therapeutics (TRVI) Tops Q2 EPS by 2c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Orosur Mining launches private placement targeting C$14M
• Progress Software completes $400M acquisition of Domo's data platform